
About Mateon Therapeutics
Mateon Therapeutics is a publicly listed company based in San Francisco (United States) founded in 1996. Vascular targeted therapies are developed for rare diseases and cancers. Mateon Therapeutics has completed 2 acquisitions, including PointR Data and Symphony Vida. Mateon Therapeutics offers products and services including OT-101, CA4P, and OXi4503. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Mateon Therapeutics, Inc. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Mateon Therapeutics is a developer of vascular targeted therapy for the treatment of rare diseases cancers. It is developing vascular targeted therapy (VTT) including vascular disrupting agents (VDAs) anti-angiogenic agents (AAs) for the treatment of rare cancers. Its drug pipeline CA4P (VDA) is being developed in combination with bevacizumab chemotherapy for platinum-resistant ovarian cancer (prOC) (Phase 23) with pazopanib for the treatment of recurrent ovarian cancer (Phase 1b2)with bevacizumab for glioblastoma multiforme (Phase 23). It has developed OXi4503 (VDA) in combination with cytarabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
- Headquarters San Francisco, United States
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website mateon.com
- Social LinkedIn X YouTube
- Legal Name Mateon Therapeutics, Inc.
- Latest Funding Round$600K (USD), Post-IPO
Apr 2019
- Investors
- Investments & AcquisitionsPointR Data
& 1 more
Products & Services of Mateon Therapeutics
Mateon Therapeutics offers a comprehensive portfolio of products and services, including OT-101, CA4P, and OXi4503.
Anti-TGF-β drug for cancer and infectious disease treatment.
Targets melanoma in rare pediatric cancers.
Treats acute myeloid leukemia in pediatric cases.
Apps and channels of Mateon Therapeutics
its YouTube channel ONCOTELIC THERAPEUTICS has 87 subscribers and 19 videos.
Videos from Mateon Therapeutics
The most watched videos on Mateon Therapeutics's YouTube channel, ONCOTELIC THERAPEUTICS (87 subscribers). Click a video to play it here.
More on ONCOTELIC THERAPEUTICS.
Funding Insights of Mateon Therapeutics
- Total Rounds 7
- Last Round Post-IPO β $600,000
- First Round $15M
(Jul 2003)
- Investors Count 1
All 7 funding rounds of Mateon Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $600,000 | Post-IPO | β | β | β |
| Apr 2018 | $2.93M | Post-IPO | β | β | β |
| Apr 2013 | $5M | Post-IPO | β | β | β |
| Nov 2010 | $733,000 | Grant | β | β | |
| Mar 2010 | $7.5M | Post-IPO | β | β | β |
| Mar 2010 | $7.5M | Post-IPO | β | β | β |
| Jul 2003 | $15M | Post-IPO | β | β | β |
1 investors in total: 1 institutional.
Investors in Mateon Therapeutics
Mateon Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Internal Revenue Service.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tax administration and collection services by the US government. | irs.gov |
Investor details for Mateon Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mateon Therapeutics
Mateon Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include PointR Data and Symphony Vida.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Edge AI computing solutions for drones and robotics are provided. | pointr.ai | San Jose, United States | 2018 | Nov 2019 | β’β’β’β’ | |
Therapeutics for cancer and eye diseases are developed. | symphonyvida.com | Rockville, United States | 0 | Jul 2009 | $12.5M |
Complete acquisition details for Mateon Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Mateon Therapeutics
6 dated milestones of Mateon Therapeutics across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Mateon Therapeutics is founded.
- Funding First funding round of $15.0M.
- Acquisition Acquires Symphony Vida.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $600K.
- Acquisition Acquires PointR Data.
Competitors of Mateon Therapeutics
Mateon Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Mateon Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Mateon Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mateon Therapeutics
Complete news archive for Mateon Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mateon Therapeutics
Mateon Therapeutics was founded in 1996 and raised its 1st funding round 7 years after it was founded.
Mateon Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Mateon Therapeutics is a developer of vascular targeted therapy for the treatment of rare diseases cancers. It is developing vascular targeted therapy (VTT) including vascular disrupting agents (VDAs) anti-angiogenic agents (AAs) for the treatment of rare cancers. Its drug pipeline CA4P (VDA) is being developed in combination with bevacizumab chemotherapy for platinum-resistant ovarian cancer (prOC) (Phase 23) with pazopanib for the treatment of recurrent ovarian cancer (Phase 1b2)with bevacizumab for glioblastoma multiforme (Phase 23). It has developed OXi4503 (VDA) in combination with cytarabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Mateon Therapeutics's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Mateon Therapeutics offers OT-101, CA4P, and OXi4503.
Mateon Therapeutics has made 2 acquisitions, including PointR Data, and Symphony Vida.
Mateon Therapeutics has 1 investor. Key investors include Internal Revenue Service.
Mateon Therapeutics operates through Mateon Therapeutics, Inc..
